VisionSys AI (ADR)
Develops BCI technical services and non-invasive EEG applications.
Something off on this page? Send us feedback.
Profile
Generates limited revenue from customized BCI technical services based on a system that uses AI-enabled software and hardware to decode brainwave and other signals. Near-term commercialization centers on non-invasive EEG and general-wellness applications, while medical and overseas applications depend on validation, approvals, market acceptance and capital.
Operates an early-stage brain-computer-interface technology and services business through Beijing Wangwen Zhisuan Technology in mainland China. Its acquired System combines brainwave, facial-expression and head-movement signals with AI-enabled algorithms for signal processing and decoding, software-hardware coordination, analysis and external-device control.
Generates limited revenue from customized technical services covering signal decoding, development, testing, optimization, implementation, device adaptation, software-hardware integration, consulting, maintenance and support. Near-term work centers on non-invasive EEG, sleep support, attention monitoring, meditation, general wellness and rehabilitation support; supplier-sourced devices may complement the service model. Medical and overseas applications depend on validation, approvals, market acceptance and capital. Operations are conducted primarily in mainland China through a Cayman holding-company structure.
Company facts
Key statistics
Year to date −86.1% · Average volume (30d) 156.1K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 29, 2023Q2 FY23 | −$12.41 | $46.18 | +472.2% | $72.2M | $75.1M | +4.0% | +0.40% |
| Jun 13, 2023Q1 FY23 | −$10.00 | −$3.40 | +66.0% | $54.8M | $56.1M | +2.3% | +2.15% |
| Mar 28, 2023Q4 FY22 | — | −$0.92 | — | — | $80.1M | — | −4.49% |
| May 25, 2021Q1 FY21 | — | −$8.28 | — | — | $81.4M | — | +1.97% |
Financial highlights
| 12 quarters | Q1 FY22 | Q2 FY22 | Q3 FY22 | Q4 FY22 | Q1 FY23 | Q2 FY23 | |
|---|---|---|---|---|---|---|---|
| Revenue | $92.8M | $96.5M | $95.7M | $82.2M | $57.3M | $81.1M | |
| Gross profit | $53.4M | $56.0M | $52.7M | $48.0M | $29.9M | $41.5M | |
| Operating income | $4.3M | $7.1M | $3.1M | −$679.7K | −$8.8M | −$1.0M | |
| Net income | $4.0M | $7.1M | $4.1M | −$2.8M | −$7.5M | $1.1M | |
| Diluted EPS | $0.35 | $0.64 | $0.36 | −$0.26 | −$0.69 | $0.10 | |
| Gross margin | 57.6% | 58.0% | 55.1% | 58.4% | 52.2% | 51.1% | |
| Operating margin | 4.6% | 7.4% | 3.3% | -0.8% | -15.3% | -1.2% |
Fiscal years (4-quarter sums)FY17 $293.7M · FY18 $310.3M · FY20 $282.4M · FY21 $355.1M · FY22 $367.2M
Balance sheet, Dec 31, 2025Cash & short-term investments $8.0M · Total debt $0 · Total assets $15.9M · Shareholders' equity $15.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 775.3K · Float 768.1K · 99.1% free float
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Compass Minerals
Sleep and EEG diagnostics overlap in institutional brain monitoring.
- Ceribell
AI-enabled portable EEG overlaps in rapid brain-signal interpretation.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| VisionSys AI (ADR) | $3.32 | −2.64% | $2.7M | 0.0 | — | 17.2 | — |
| Compass Minerals | $24.62 | −0.06% | $1.03B | 57.3 | 21.1 | 0.8 | +0.3% |
| Ceribell | $23.73 | +0.17% | $900.4M | — | — | 8.8 | +32.5% |
| Median | 57.3 | 21.1 | 4.8 | +16.4% |